» Articles » PMID: 12640143

Targeted Inhibition of Stat3 with a Decoy Oligonucleotide Abrogates Head and Neck Cancer Cell Growth

Overview
Specialty Science
Date 2003 Mar 18
PMID 12640143
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

The transcription factor signal transducer and activator of transcription 3 (Stat3) is constitutively activated in a variety of cancers including squamous cell carcinoma of the head and neck (SCCHN). Previous investigations have demonstrated that activated Stat3 contributes to a loss of growth control and transformation. To investigate the therapeutic potential of blocking Stat3 in cancer cells, we developed a transcription factor decoy to selectively abrogate activated Stat3. The Stat3 decoy was composed of a 15-mer double-stranded oligonucleotide, which corresponded closely to the Stat3 response element within the c-fos promoter. The Stat3 decoy bound specifically to activated Stat3 and blocked binding of Stat3 to a radiolabeled Stat3 binding element. By contrast, a mutated version of the decoy that differed by only a single base pair did not bind the activated Stat3 protein. Treatment of head and neck cancer cells with the Stat3 decoy inhibited proliferation and Stat3-mediated gene expression, but did not decrease the proliferation of normal oral keratinocytes. Thus, disruption of activated Stat3 by using a transcription factor decoy approach may serve as a novel therapeutic strategy for cancers characterized by constitutive Stat3 activation.

Citing Articles

STAT3: Key targets of growth-promoting receptor positive breast cancer.

Jiang R, Zhu J, Zhang H, Yu Y, Dong Z, Zhou H Cancer Cell Int. 2024; 24(1):356.

PMID: 39468521 PMC: 11520424. DOI: 10.1186/s12935-024-03541-9.


Blocking M2-Like Macrophage Polarization Using Decoy Oligodeoxynucleotide-Based Gene Therapy Prevents Immune Evasion for Pancreatic Cancer Treatment.

Chen C, Wang H, Hou Y, Wu Y, Shieh C, Shan Y Mol Cancer Ther. 2024; 23(10):1431-1445.

PMID: 38907533 PMC: 11443249. DOI: 10.1158/1535-7163.MCT-23-0767.


Natural Prenylflavones from the Stem Bark of : Promising Anticancer Agents for Oral Squamous Cell Carcinoma Targeting the Akt/mTOR/STAT-3 Signaling Pathway.

Aswathy M, Parama D, Hegde M, Dr S, Lankalapalli R, Radhakrishnan K ACS Omega. 2024; 9(23):24252-24267.

PMID: 38882137 PMC: 11170706. DOI: 10.1021/acsomega.3c08376.


Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.

Shen Y, Thng D, Wong A, Toh T Exp Hematol Oncol. 2024; 13(1):40.

PMID: 38615034 PMC: 11015656. DOI: 10.1186/s40164-024-00512-8.


Role of STAT3 in cancer cell epithelial‑mesenchymal transition (Review).

Zhang G, Hou S, Li S, Wang Y, Cui W Int J Oncol. 2024; 64(5).

PMID: 38488027 PMC: 11000535. DOI: 10.3892/ijo.2024.5636.


References
1.
Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K . Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002; 62(12):3351-5. View

2.
Li L, Shaw P . Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J Biol Chem. 2002; 277(20):17397-405. DOI: 10.1074/jbc.M109962200. View

3.
Kijima T, Niwa H, Steinman R, Drenning S, Gooding W, Wentzel A . STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 2002; 13(8):355-62. View

4.
Heo D, Snyderman C, Gollin S, Pan S, Walker E, Deka R . Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res. 1989; 49(18):5167-75. View

5.
Riser B, Mitra R, Perry D, Dixit V, Varani J . Monocyte killing of human squamous epithelial cells: role for thrombospondin. Cancer Res. 1989; 49(21):6123-9. View